EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access

Magnetic Resonance Imaging, Clinical, and Biopsy Findings in Suspected Prostate Cancer

Arya Haj-Mirzaian, Kristine S Burk, Ronilda Lacson, Daniel I Glazer, Sanjay Saini, Adam S Kibel, Ramin Khorasani

JAMA Network Open · 29.03.2024 · 7 (3) · e244258

DOI: 10.1001/jamanetworkopen.2024.4258 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift JAMA Network Open, online erschienen am 29.03.2024. Verfasst von Arya Haj-Mirzaian und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Evidence-Based Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Hauptthemen laut MEDLINE: Magnetic Resonance Imaging, Prostatic Neoplasms. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: AHRQ HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Multiple strategies integrating magnetic resonance imaging (MRI) and clinical data have been proposed to determine the need for a prostate biopsy in men with suspected clinically significant prostate cancer (csPCa) (Gleason score ≥3 + 4). However, inconsistencies across different strategies create challenges for drawing a definitive conclusion.

Objective

To determine the optimal prostate biopsy decision-making strategy for avoiding unnecessary biopsies and minimizing the risk of missing csPCa by combining MRI Prostate Imaging Reporting & Data System (PI-RADS) and clinical data. Data Sources PubMed, Ovid MEDLINE, Embase, Web of Science, and Cochrane Library from inception to July 1, 2022. Study Selection English-language studies that evaluated men with suspected but not confirmed csPCa who underwent MRI PI-RADS followed by prostate biopsy were included. Each study had proposed a biopsy plan by combining PI-RADS and clinical data. Data Extraction and Synthesis Studies were independently assessed for eligibility for inclusion. Quality of studies was appraised using the Quality Assessment of Diagnostic Accuracy Studies 2 tool and the Newcastle-Ottawa Scale. Mixed-effects meta-analyses and meta-regression models with multimodel inference were performed. Reporting of this study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline. Main Outcomes and Measures Independent risk factors of csPCa were determined by performing meta-regression between the rate of csPCa and PI-RADS and clinical parameters. Yields of different biopsy strategies were assessed by performing diagnostic meta-analysis.

Results

The analyses included 72 studies comprising 36 366 patients. Univariable meta-regression showed that PI-RADS 4 (β-coefficient [SE], 7.82 [3.85]; P = .045) and PI-RADS 5 (β-coefficient [SE], 23.18 [4.46]; P < .001) lesions, but not PI-RADS 3 lesions (β-coefficient [SE], −4.08 [3.06]; P = .19), were significantly associated with a higher risk of csPCa. When considered jointly in a multivariable model, prostate-specific antigen density (PSAD) was the only clinical variable significantly associated with csPCa (β-coefficient [SE], 15.50 [5.14]; P < .001) besides PI-RADS 5 (β-coefficient [SE], 9.19 [3.33]; P < .001). Avoiding biopsy in patients with lesions with PI-RADS category of 3 or less and PSAD less than 0.10 (vs <0.15) ng/mL 2 resulted in reducing 30% (vs 48%) of unnecessary biopsies (compared with performing biopsy in all suspected patients), with an estimated sensitivity of 97% (vs 95%) and number needed to harm of 17 (vs 15). Conclusions and Relevance These findings suggest that in patients with suspected csPCa, patient-tailored prostate biopsy decisions based on PI-RADS and PSAD could prevent unnecessary procedures while maintaining high sensitivity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Magnetic Resonance ImagingProstatic NeoplasmsMaleHumansProstate-Specific AntigenProstateBiopsy

Substanzen

Prostate-Specific Antigen

Autor:innen und Institutionen

  • Center for Evidence-Based Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Division of Urological Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

Förderung

  • AHRQ HHS

Zitieren

APA

Haj-Mirzaian, A., Burk, K. S., Lacson, R., Glazer, D. I., Saini, S., Kibel, A. S., & Khorasani, R. (2024). Magnetic Resonance Imaging, Clinical, and Biopsy Findings in Suspected Prostate Cancer. JAMA Network Open, 7(3), e244258. https://doi.org/10.1001/jamanetworkopen.2024.4258

Vancouver

Haj-Mirzaian A, Burk KS, Lacson R, Glazer DI, Saini S, Kibel AS, et al. Magnetic Resonance Imaging, Clinical, and Biopsy Findings in Suspected Prostate Cancer. JAMA Network Open. 2024;7(3):e244258. doi:10.1001/jamanetworkopen.2024.4258

BibTeX
@article{HajMirzaian2024,
  author = {Haj-Mirzaian, Arya and Burk, Kristine S and Lacson, Ronilda and Glazer, Daniel I and Saini, Sanjay and Kibel, Adam S and Khorasani, Ramin},
  title = {Magnetic Resonance Imaging, Clinical, and Biopsy Findings in Suspected Prostate Cancer},
  journal = {JAMA Network Open},
  year = {2024},
  volume = {7},
  number = {3},
  pages = {e244258},
  doi = {10.1001/jamanetworkopen.2024.4258}
}
Kostenlos starten →